Navigation Links
Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278

Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278 -- CORK, Ireland, September 3, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services, Clinical Trials & Medical Discoveries Click to view news release full screen  

Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278


CORK, Ireland, September 3, 2010 /PRNewswire/ -- Tibotec Pharmaceuticals today announced its submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TMC278 (rilpivirine, as hydrochloride), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV. The proposed indication would make TMC278 available for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults.

It is estimated that 33.4 million people are living with HIV worldwide,[1] 2.3 million of which are in Europe.[2] Research shows that antiretrovirals have helped to extend life expectancy for people living with HIV.[3] However, new treatments are needed which suppress the replication of the virus while also minimizing the occurrence of unwanted side effects.[4]

The TMC278 filing is based on an extensive global clinical development programme involving more than 1,350 patients[5] in over 20 countries. If approved, TMC278 would help to expand the treatment options for people living with HIV.

"Thanks to advances in treatment, people with HIV are living longer than ever before, which is made possible by continuous research for new and improved treatments," said Eric Lefebvre, Medical Director at Tibotec. "The EMA regulatory submission for TMC278 represents an important part of our ongoing commitment to HIV and to helping patients receive the treatment and care they need."

Pending EMA approval, Tibotec will commercialize TMC278 in the European Union. Tibotec has also submitted new drug applications in the US and Canada, and regulatory submissions for TMC278 in other countries are expected in the coming months. Tibotec has entered into a license and collaboration agreement with Gilead Sciences, Inc. (Nasdaq: GILD) for the development and commercialization of a once-daily fixed-dose combination of TMC278 and Gilead's Truvada(R) (emtricitabine and tenofovir disoproxil (as fumarate)).

About TMC278

TMC278 is an investigational NNRTI, which blocks the reverse transcriptase, a key enzyme the HIV virus uses to replicate. The regulatory application for TMC278 is based on the 48-week results of two pivotal Phase 3 double-blind, randomized studies recently presented at the International AIDS Congress, known as ECHO (TMC278-TiDP6-C209) and THRIVE (TMC278-TiDP6-C215).5 The studies evaluated the efficacy, safety and tolerability of once-daily TMC278, in combination with two NRTIs, in treatment-naive HIV-1-infected adults, and both reached their primary objective of demonstrating non-inferiority of TMC278 vs. efavirenz in the percentage of patients achieving an undetectable viral load (less than 50 copies/mL) at week 48 (with a maximum allowable difference of 12 percent).5 The studies showed that TMC278 demonstrated significant improvements in tolerability, with lower rates of discontinuations due to adverse events including dizziness, abnormal dreams and nightmares, and rashes.5

About Tibotec Pharmaceuticals

Tibotec Pharmaceuticals, based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Beerse, Belgium, with offices in Titusville, NJ, USA. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need.

About Tibotec, a division of Janssen-Cilag

Tibotec, a division of Janssen-Cilag, brings innovative products for HIV/AIDS to patients in Europe, the Middle East and Africa focusing on patients' and healthcare providers' specific needs in this disease domain. The company will also commercialise medicines to combat other viral diseases in the future.

About Janssen-Cilag

Janssen-Cilag is a leader in traditional and biological medicines in areas such as gastroenterology, women's health, mental health and neurology as well as for pain, oncology, haematology and nephrology.

Tibotec Pharmaceuticals and Janssen-Cilag are subsidiaries of the Johnson & Johnson family of companies.

Truvada is a registered trademark of Gilead Sciences, Inc.



[1] World Health Organization: HIV Global epidemic data and statistics. Available at: Last accessed: August 2010

[2] Avert: European HIV and AIDS Statistics. Available at: Last accessed: August 2010

[3] Lewden C. Responders to antiretroviral treatment over 500 CD4/mm3 reach same mortality rates as general population: APROCO and Aquitaine Cohorts. 10th European AIDS Conference abstract. 2005. PE18.4/8.

[4] HIV/AIDS Outlook: The Outlook for a Cure. Available at: Last accessed: August 2010

[5] Cohen C et al. Pooled Week 48 efficacy and safety results from ECHO andTHRIVE, two double-blind, randomised, Phase III trials comparing TMC278 versus efavirenz in treatment-naive, HIV-1-infected patients. IAC abstract. 2010.

SOURCE Tibotec Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers
2. Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS
3. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
4. Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
5. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
6. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
7. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
8. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
9. Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification
10. Transdel Pharmaceuticals Presents Phase 3 Study Data on Ketotransdel® at World Pain Congress in Montreal, Canada
11. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):